Answers are grounded in this paper and cite their sources.
This study aimed to elucidate the mechanism by which mitochondrial DNA (mtDNA) leakage mediates autophagic ferroptosis in astrocytes and facilitates the progression of Alzheimer’s disease (AD). In vitro, an AD cell model was established by exposing mouse C8-D1A astrocytes to Aβ-42, followed by treatment with the mitochondrial permeability transition pore (mPTP) inhibitor cyclosporin A (CsA) and autophagy inhibitor 3-MA. In vivo, APP/PS1 transgenic AD mice received stereotaxic bilateral hippocampal injection of CsA, autophagy agonist rapamycin (RAPA), or Erastin. Cell viability, subcellular distribution of mtDNA, mPTP opening degree, activation of the cGAS-STING pathway, cognitive function of mice, hippocampal pathological injury, as well as markers related to autophagy and ferroptosis were detected. In vitro results demonstrated that Aβ-42 stimulation triggered robust mtDNA release in astrocytes, activated the cGAS-STING pathway to boost autophagy, and consequently aggravated ferroptosis. Blocking mtDNA leakage suppressed the cGAS-STING cascade and attenuated autophagy, thereby alleviating ferroptosis and AD-related pathological phenotypes; such protective effects could be partially abolished by autophagy activation or ferroptosis induction. In vivo experiments further confirmed that inhibition of mtDNA leakage effectively ameliorated cognitive deficits and hippocampal lesions in AD model mice. In conclusion, mtDNA leakage drives AD progression via cGAS-STING-dependent autophagic ferroptosis in astrocytes, and suppression of mtDNA leakage may serve as a novel therapeutic strategy for AD.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: